Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Cash (2016 - 2025)

United Therapeutics' Change in Cash history spans 17 years, with the latest figure at $217.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 51.43% year-over-year to $217.0 million; the TTM value through Dec 2025 reached -$140.1 million, down 128.62%, while the annual FY2025 figure was -$140.1 million, 128.62% down from the prior year.
  • Change in Cash for Q4 2025 was $217.0 million at United Therapeutics, up from -$253.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $217.0 million in Q4 2025 and bottomed at -$306.8 million in Q2 2025.
  • The 5-year median for Change in Cash is $68.7 million (2021), against an average of $40.9 million.
  • The largest YoY upside for Change in Cash was 1885.71% in 2023 against a maximum downside of 431.49% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$13.7 million in 2021, then soared by 59.12% to -$5.6 million in 2022, then soared by 1885.71% to $100.0 million in 2023, then skyrocketed by 43.3% to $143.3 million in 2024, then soared by 51.43% to $217.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Change in Cash are $217.0 million (Q4 2025), -$253.0 million (Q3 2025), and -$306.8 million (Q2 2025).